EE46 High Doses of Treprostinil Could Entail Lower Hospitalization Costs in Patients With Pulmonary Arterial Hypertension in Nine European Countries

Treprostinil is a prostacyclin analogue indicated for the treatment of pulmonary arterial hypertension (PAH). A recent retrospective study analyzed the drug safety events of treprostinil and showed that higher doses were associated with lower hospitalization rates compared to lower doses. This analysis aims to estimate annual PAH-related hospitalization costs in patients treated with low, medium and high treprostinil doses in nine European countries (Belgium, France, Germany, Italy, Poland, Portugal, Spain, the Netherlands and the United Kingdom).